About Idiopathic Pulmonary Fibrosis (IPF)
IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, which is the most prevalent of a classification of lung disorders known as interstitial lung diseases (ILD's). There is currently no known cause or cure for IPF, nor is there an FDA-approved treatment. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose, and an estimated two- thirds of patients die within five years of diagnosis.
About the Coalition for Pulmonary Fibrosis
The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit
organization, founded in 2001 to accelerate research efforts leading to a
cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting,
and advocating for the community of patients, families, and medical
professionals fighting this disease. The CPF funds promising research into
new approaches to treat and cure pulmonary fibrosis; provides patients and
families with comprehensive education materials, resources, and hope;
serves as a voice for national advocacy of IPF issues; and works to i
|SOURCE Coalition for Pulmonary Fibrosis|
Copyright©2008 PR Newswire.
All rights reserved